Lower Cross SyndromeNCT07526051
Effects of Autogenic Inhibition Versus Reciprocal Inhibition in Individuals With Lower Cross Syndrome
A study testing Autogenic Inhibition (PFS) Group A and Reciprocal Inhibition Group B in people with Lower Cross Syndrome, run by Foundation University Islamabad at 1 site in Pakistan.
Trial summary
This study examines the effects of autogenic inhibition (PFS) versus reciprocal inhibition in individuals with lower cross syndrome Read more about this study
- Who is it for?
- Ages 25 to 50 years
- Conditions the study is for
- Lower Cross Syndrome
- What is being tested?
- Autogenic Inhibition (PFS) Group A and Reciprocal Inhibition Group B
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 72 participants
- Where
- 1 sitePakistan
- Study dates
- 20 May 2026to 15 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Both Males and Females will be included in our study Age 25-50 years Four positive screening tests (Thomas Test, Abdominal Strength Test, Glutues Maximus Test, Ely's Test) chronic Pain in lower Back Region (>3 on VAS) lasting for more than 2 months
Who cannot join
- Osteoporosis Congenital Hip Dysplasia History of Fracture History of Inflammatory Arthritis Pregnancy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
Foundation University College of Physical Therapy
Islamabad, Punjab Province, 46000
Zobia Noor, DPT, 0334-8962818, zobianoor426@gmail.com
Ruqia Begum, MS-OMPT, 03115532544, ruqia@fui.edu.pk
About this study
This study examines the effects of autogenic inhibition (PFS) versus reciprocal inhibition in individuals with lower cross syndrome
Read the detailed description
Participants were randomly assigned into two groups Group A received Autogenic Inhibition (PFS) technique focusing on lengthening of chronically shortened muscles Group B received Reciprocal Inhibition technique focusing on lengthening of chronically shortened muscles Pain, Functional Disability , Muscular strength, Lumbar and Hip Rom were measured using VAS, ODI, Sphygmomanometer, Inclinometer and Goniometer
- Conditions
- Lower Cross Syndrome
- Being tested
- Autogenic Inhibition (PFS) Group A, Reciprocal Inhibition Group B
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Autogenic Inhibition (PFS) Group AProcedure or surgery
Patient will receive a four-week physiotherapy program with 3 sessions per week. Each session with heat application followed by supervised stretching and strengthening exercises.
Participants in group A will receive Autogenic Inhibition (PFS) 10 minutes TENS \& Heating Pad Autogenic Inhibition for 5 sec 5 reps, 5 sec hold,1 set Frequency: 12 sessions for 4 weeks (3 sessions per week and day of rest between sessions) Total Treatment Time 30 minutes each session Strengthening Exercises for Hip and Core Muscles
Reciprocal Inhibition Group BProcedure or surgery
Patient will receive a four-week physiotherapy program with 3 sessions per week. Each session with heat application followed by supervised stretching and strengthening exercises. Participants in group B will receive Reciprocal Inhibition 10 minutes TENS \& Heating Pad Inhibition for 5 sec 5 reps,5 sec hold,1 set Frequency: 12 sessions for 4 weeks (3 sessions per week and day of rest between sessions) Total Treatment Time 30 minutes each session Strengthening Exercises for Hip and Core Muscles
| Study group | Role | What they receive |
|---|---|---|
| Group A:Autogenic Inhibition(PFS) | Experimental | Group A will receive Autogenic Inhibition (PFS) Technique 10 minutes TENS \& Heating Pad Autogenic Inhibition Technique for 5 sec 5 reps*5 sec hold*1 set Strengthening exercises for hip extensors and core muscles Receives: Procedure: Autogenic Inhibition (PFS) Group A |
| Group B: Reciprocal Inhibition | Experimental | Group B will receive Reciprocal Inhibition Technique 10 minutes TENS \& Heating Pad Reciprocal Inhibition Technique for 5 sec 5 reps*5 sec hold*1 set Strengthening exercises for hip extensors and core muscles Receives: Procedure: Reciprocal Inhibition Group B |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lumbar Range of Motion
Lumbar spine range of motion will be assessed using inclinometer
Measured: Baseline, 2nd week and 4th week
Hip Range of Motion
Hip range of motion will be assessed using Goniometer
Measured: Baseline, 2nd week and 4th week
Functional Disability
Functional Disability will be measured with Oswestry disability Index, a ten item questionnaire with 6 response options per item.
Measured: Baseline, 2nd week and 4th week
Secondary outcomes (2)
Pain Intensity
Pain intensity will be measured with VAS ranging from 0 (no pain) to 10 (worst pain)
Measured: Baseline, 2nd week and 4th week
Muscles Strength (Gluteus & Core Muscles)
Muscles strength will be assessed using sphygmomanometer
Measured: Baseline, 2nd week and 4th week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start20 May 2026 (estimated)
- Primary completion1 Jul 2026 (estimated)
- Study completion15 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lower Cross SyndromeStudies of the same condition, open and under way.
- More trials run by Foundation University IslamabadThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 72 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Foundation University Islamabad
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Zobia Noor, DPT, Principal investigator, Foundation University Islamabad
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07526051
- Sponsor's protocol ID
- UI/FUCP/CTR/04.26/ZobiaNoor
- Status last verified
- May 2026
- First submitted
- 6 Apr 2026
- Last updated
- 20 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Autogenic Inhibition Versus Reciprocal Inhibition in Individuals With Lower Cross Syndrome
- ClinicalTrials.gov ID
- NCT07526051
- Acronym / sponsor ID
- UI/FUCP/CTR/04.26/ZobiaNoor
- Conditions
- Lower Cross Syndrome
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- Foundation University IslamabadUniversity, hospital or other
- Study start
- 20 May 2026 (estimated)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 15 Jul 2026 (estimated)
- First posted
- 13 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study examines the effects of autogenic inhibition (PFS) versus reciprocal inhibition in individuals with lower cross syndrome
Detailed description
Participants were randomly assigned into two groups Group A received Autogenic Inhibition (PFS) technique focusing on lengthening of chronically shortened muscles Group B received Reciprocal Inhibition technique focusing on lengthening of chronically shortened muscles Pain, Functional Disability , Muscular strength, Lumbar and Hip Rom were measured using VAS, ODI, Sphygmomanometer, Inclinometer and Goniometer
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A:Autogenic Inhibition(PFS) | Experimental | Procedure: Autogenic Inhibition (PFS) Group AGroup A will receive Autogenic Inhibition (PFS) Technique 10 minutes TENS \& Heating Pad Autogenic Inhibition Technique for 5 sec 5 reps*5 sec hold*1 set Strengthening exercises for hip extensors and core muscles |
| Group B: Reciprocal Inhibition | Experimental | Procedure: Reciprocal Inhibition Group BGroup B will receive Reciprocal Inhibition Technique 10 minutes TENS \& Heating Pad Reciprocal Inhibition Technique for 5 sec 5 reps*5 sec hold*1 set Strengthening exercises for hip extensors and core muscles |
Who may qualify
- Ages
- 25 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Both Males and Females will be included in our study Age 25-50 years Four positive screening tests (Thomas Test, Abdominal Strength Test, Glutues Maximus Test, Ely's Test) chronic Pain in lower Back Region (>3 on VAS) lasting for more than 2 months
Key exclusion criteria (1 listed)
- Osteoporosis Congenital Hip Dysplasia History of Fracture History of Inflammatory Arthritis Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Autogenic Inhibition (PFS) Group APatient will receive a four-week physiotherapy program with 3 sessions per week. Each session with heat application followed by supervised stretching and strengthening exercises. Participants in group A will receive Autogenic Inhibition (PFS) 10 minutes TENS \& Heating Pad Autogenic Inhibition for 5 sec 5 reps, 5 sec hold,1 set Frequency: 12 sessions for 4 weeks (3 sessions per week and day of rest between sessions) Total Treatment Time 30 minutes each session Strengthening Exercises for Hip and Core Muscles | Procedure or surgery | Group A:Autogenic Inhibition(PFS) |
| Reciprocal Inhibition Group BPatient will receive a four-week physiotherapy program with 3 sessions per week. Each session with heat application followed by supervised stretching and strengthening exercises. Participants in group B will receive Reciprocal Inhibition 10 minutes TENS \& Heating Pad Inhibition for 5 sec 5 reps,5 sec hold,1 set Frequency: 12 sessions for 4 weeks (3 sessions per week and day of rest between sessions) Total Treatment Time 30 minutes each session Strengthening Exercises for Hip and Core Muscles | Procedure or surgery | Group B: Reciprocal Inhibition |
Primary outcome
Lumbar Range of Motion
Time frame: Baseline, 2nd week and 4th week
Lumbar spine range of motion will be assessed using inclinometer
Hip Range of Motion
Time frame: Baseline, 2nd week and 4th week
Hip range of motion will be assessed using Goniometer
Functional Disability
Time frame: Baseline, 2nd week and 4th week
Functional Disability will be measured with Oswestry disability Index, a ten item questionnaire with 6 response options per item.
2 secondary outcomes
Pain Intensity
Time frame: Baseline, 2nd week and 4th week
Muscles Strength (Gluteus & Core Muscles)
Time frame: Baseline, 2nd week and 4th week
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2026.
Related trials for Lower Cross Syndrome
Recruiting
Comparative Effects of Autogenic Inhibition vs Reciprocal Inhibition in Patients With Lower Cross Syndrome
Lower Cross Syndrome
Recruiting
Effects of Post-Isometric Relaxation and Myofascial Release on Low Back Pain With Lower Cross Syndrome
Low Back Pain, Mechanical, Lower Cross Syndrome
Not yet recruiting
Effects of Sahrmann's Versus Janda Approach in Lower Crossed Syndrome Patients
Lower Cross Syndrome
Recruiting
Effects of Lumber Sustained Natural Apophyseal Glides on Lower Cross Syndrome
Lower Cross Syndrome
Recruiting
Effects Of Jandas Approach Vs PNF Technique On Pain, ROM, Disability, Endurance And QOL In Patients With LCS
Lower Cross Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Zobia Noor, DPT principal investigator
Foundation University Islamabad
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Autogenic Inhibition (PFS) Group A and Reciprocal Inhibition Group B in people with Lower Cross Syndrome, run by Foundation University Islamabad at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zobia Noor, DPT (0334-8962818, zobianoor426@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lumbar Range of Motion (time frame: Baseline, 2nd week and 4th week). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2026; AzTrials last refreshed its copy on 8 Nov 2026.